Oncoceutics, Inc. announced that the European Patent Office (EPO) has issued EP 3,068,401 entitled “7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Use” with an expiration date of September 12, 2034.
Philadelphia, PA (March 4, 2019) –Oncoceutics, Inc. announced that the European Patent Office (EPO) has issued EP 3,068,401 entitled “7-benzyl-4-(2-methylbenzyl)-
ONC206, a member of the imipridone family of anti-cancer small molecules, has demonstrated anti-cancer activity and safety in preclinical models and is planned to enter the clinic in 2019. These patents pave the path for the next generation of imipridones to enter the clinic and eventually the market.
This patent is the second issued on ONC206, following the composition of matter patent issued by the US Patent Office on June 28th, 2016, and greatly expands the company’s global IP protection.
“We are pleased that the European Patent Office has recognized ONC206 as an exciting novel invention and granted the appropriate patent protections,” said Martin Stogniew, Ph.D., Chief Development Officer of Oncoceutics. “The company’s current patent portfolio provides Oncoceutics with the opportunity to continue imipridone development and eventually provide ONC206 to European patients.”
About Oncoceutics
Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds, i.e. the “imipridones,” that selectively target G protein-coupled receptors for oncology. The first lead compound to emerge from this program is ONC201, an orally active small molecule DRD2 antagonist. The company is supported by grants from NCI, FDA, Musella Foundation, XCures, Cancer Commons, and a series of private and public partnerships.
Visit Oncoceutics for more information.
